Nemes E, et al. - Researchers performed a double-blind, randomized, controlled trial comparing newborn MVA85A prime vaccination (1 × 10⁸ PFU) vs Candin control, followed by selective, deferred bacille Calmette-Guérin (BCG) vaccination at age 8 weeks for human immunodeficiency virus (HIV)-uninfected infants. They performed 12 months follow-up for safety and immunogenicity. In HIV-exposed newborns, MVA85A prime vaccination was safe. It induced an early modest antigen-specific immune response that did not interfere with, or enhance, immunogenicity of subsequent BCG vaccination.